Co-founded with Memorial Sloan Kettering Cancer Center, Mnemo Therapeutics is a biotechnology company focused on developing powerful cell therapies that create accessible cures. With its EnfiniT platform, a groundbreaking drug discovery engine, Mnemo applies a novel, integrated approach to cell therapy. Through precise identification of a new class of antigens with greater target specificity and the ability to efficiently reprogram T cells to increase their memory phenotype, as well as refine their engineering, Mnemo will transform the body’s immune response to overcome currently incurable diseases.
Year of creation: 2019
Line of business: Biotechnology
Institut Curie: Incubator, institutional co-founder and R&D partner
Mnemo is using its EnfiniT platform, an integrated drug discovery engine that combines:
- A proprietary combination of epigenetics tools assembled into powerful T cell engineering technologies
- A revolutionary target ID engine that sources newly-identified junctions between exons and transposable elements (JETs)
- Best-in-class manufacturing
Mnemo is built by a transatlantic team of scientists and biotech leaders united in a quest to create the most powerful immune therapies to deliver accessible cures for all patients in need.
More about Mnemo Therapeutics: